Clinical Utility

PromarkerD enables a more comprehensive assessment and informed approach to help:

  • Identify patients at risk of developing DKD within the next four years
  • Implement preventative measures before kidney damage occurs
  • Personalise patient treatment plans
  • Improve patient monitoring and management
  • Results published in the peer-reviewed journal PLOS ONE show the PromarkerD test ranked as more important to physicians than current standard-of-care tests

What can be done?

Early stage chronic kidney disease can be treated through dietary changes, lifestyle modifications and blood pressure controlling drugs, all of which ensure a relatively better quality of life.

  • Janssen’s Invokana® (canagliflozin) – the first FDA approved drug for treating DKD
  • Currently ~20 DKD drugs are at different stages of clinical trials
  • American Diabetes Association (ADA) & the European Association for the Study of Diabetes (EASD) latest guidelines¹ on managing Type 2 Diabetes recommend that patients with cardiovascular disease take a GLP-1 receptor agonist or SGLT2 inhibitor.

Early detection can significantly help prevent serious kidney damage

1. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia; Diabetes Care